"Biomarkers can be challenging to understand in CIDP because of the rarity and heterogeneity of the disease," said Jeffrey ...

In 2024, the Food and Drug Administration (FDA) approved Vyvgart Hytrulo, a new effective treatment for CIDP in adults. Vyvgart Hytrulo works by reducing the level of pathogenic (disease-causing ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

and those with obvious underlying secondary CIDP etiologies including diabetes, autoantibodies, or an IgM monoclonal gammopathy. Patients with hypertension, other medical disorders preventing ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) is the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

Inflammatory disorders often cause myelin damage, but there are other causes. When you think of myelin, imagine the insulation around an electrical wire. Damage to myelin can make it harder for ...

Gene therapy researchers have treated two boys with X-linked adrenoleukodystrophy (X-ALD), a demyelinating disease highlighted in the movie “Lorenzo's Oil.” Such individuals are normally ...